Capricor Therapeutics (CAPR) 10-Q 14 Nov 13 2013 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Sep. 30, 2013	Nov. 12, 2013
Document Information [Line Items]	'	'
Entity Registrant Name	'Nile Therapeutics, Inc.	'
Entity Central Index Key	'0001133869	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Trading Symbol	'NLTX	'
Entity Common Stock, Shares Outstanding	'	43,520,563
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'
Document Fiscal Period Focus	'Q3	'
Document Fiscal Year Focus	'2013	'

CONDENSED_BALANCE_SHEETS

CONDENSED BALANCE SHEETS (USD $)	Sep. 30, 2013	Dec. 31, 2012
Current assets	'	'
Cash and cash equivalents	$71,028	$46,716
Prepaid expenses and other current assets	37,975	124,912
Total current assets	109,003	171,628
Property and equipment, net	828	3,488
Other noncurrent assets	4,535	51,938
Total assets	114,366	227,054
Current liabilities	'	'
Accounts payable	339,245	182,916
Accrued expenses and other current liabilities	497,886	131,928
Notes payable, net of unamortized discount of $123,204	326,796	0
Due to related party	18,000	16,139
Total current liabilities	1,181,927	330,983
Warrant liability	499,993	63,384
Total liabilities	1,681,920	394,367
Commitments and contingencies	'	'
Stockholders' deficit	'	'
Preferred stock, $0.001 par value, 10,000,000 shares authorized, none issued and outstanding	0	0
Common stock, $0.001 par value, 100,000,000 shares authorized, 43,520,563 and 43,062,231 shares issued and outstanding	43,521	43,062
Additional paid-in capital	46,525,778	46,497,642
Deficit accumulated during the development stage	-48,136,853	-46,708,017
Total stockholders' deficit	-1,567,554	-167,313
Total liabilities and stockholders' deficit	$114,366	$227,054

CONDENSED_BALANCE_SHEETS_Paren

CONDENSED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Debt instrument, unamortized discount, net	$123,204	$0
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	43,520,563	43,062,231
Common stock, shares outstanding	43,520,563	43,062,231

CONDENSED_STATEMENTS_OF_OPERAT

CONDENSED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended		98 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Income:	'	'	'	'	'
Grant income	$0	$0	$0	$0	$482,235
Collaboration income	0	0	0	195,500	1,550,000
Total income	0	0	0	195,500	2,032,235
Operating expenses:	'	'	'	'	'
Research and development	30,882	179,142	130,002	976,945	31,149,822
General and administrative	261,083	397,170	908,178	1,339,159	18,846,049
Total operating expenses	291,965	576,312	1,038,180	2,316,104	49,995,871
Loss from operations	-291,965	-576,312	-1,038,180	-2,120,604	-47,963,636
Other income (expense):	'	'	'	'	'
Interest income	57	309	200	1,149	795,392
Interest expense	-68,282	0	-155,345	0	-1,429,079
Other income (expense)	11,737	9,771	-235,511	428,410	460,470
Total other income (expense)	-56,488	10,080	-390,656	429,559	-173,217
Net loss	($348,453)	($566,232)	($1,428,836)	($1,691,045)	($48,136,853)
Basic and diluted loss per share (in dollars per share)	($0.01)	($0.01)	($0.03)	($0.04)	'
Weighted-average common shares outstanding (in shares)	43,366,125	43,062,231	43,164,642	41,912,961	'

CONDENSED_STATEMENT_OF_STOCKHO

CONDENSED STATEMENT OF STOCKHOLDERS' (DEFICIT) EQUITY (USD $)

Total

Founders

Licensing Agreement

Note Conversion

Employee

Non Employee

Accrued Liabilities

Period Issuance01

Period Issuance02

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

ADDITIONAL PAID-IN CAPITAL

ADDITIONAL PAID-IN CAPITAL

ADDITIONAL PAID-IN CAPITAL

ADDITIONAL PAID-IN CAPITAL

ADDITIONAL PAID-IN CAPITAL

ADDITIONAL PAID-IN CAPITAL

ADDITIONAL PAID-IN CAPITAL

ADDITIONAL PAID-IN CAPITAL

ADDITIONAL PAID-IN CAPITAL

DEFICIT ACCUMULATED DURING THE DEVELOPMENT STAGE

Licensing Agreement

Licensing Agreement

Founders

Licensing Agreement

Period Issuance01

Period Issuance02

Founders

Licensing Agreement

Note Conversion

Employee

Non Employee

Accrued Liabilities

Period Issuance01

Period Issuance02

Licensing Agreement

Licensing Agreement

Licensing Agreement

Licensing Agreement

Beginning Balance at Jul. 31, 2005

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common shares

'

5,000

'

'

'

'

'

'

'

'

13,794

'

'

'

'

-8,794

'

'

'

'

'

'

'

'

Issuance of common shares (in shares)

'

'

'

'

'

'

'

'

'

'

13,794,132

'

'

'

'

'

'

'

'

'

'

'

'

'

Founders shares returned to treasury

'

'

'

'

'

'

'

'

'

-1,379,419

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-10,043

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-10,043

Ending Balance at Dec. 31, 2005

-5,043

'

'

'

'

'

'

'

'

13,794

'

'

'

'

-8,794

'

'

'

'

'

'

'

'

-10,043

Ending Balance (in shares) at Dec. 31, 2005

'

'

'

'

'

'

'

'

'

12,414,713

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common shares

'

'

500

'

'

'

'

'

'

'

'

'

'

'

'

'

500

'

'

'

'

'

'

'

Issuance of common shares (in shares)

'

'

'

'

'

'

'

'

'

'

'

1,379,419

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

10,000

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000

'

'

'

'

'

'

'

'

'

Net loss

-2,581,972

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-2,581,972

Ending Balance at Dec. 31, 2006

-2,576,515

'

'

'

'

'

'

'

'

13,794

'

'

'

'

1,706

'

'

'

'

'

'

'

'

-2,592,015

Ending Balance (in shares) at Dec. 31, 2006

'

'

'

'

'

'

'

'

'

13,794,132

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common shares

'

'

'

'

'

'

'

182,236

1,000,000

'

'

'

64

350

'

'

'

'

'

'

'

182,172

999,650

'

Issuance of common shares (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

63,478

350,107

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

'

'

'

'

1,902,298

-667

'

'

'

'

'

'

'

'

'

'

'

'

1,902,298

-667

'

'

'

'

Units sold in private placement, net of issuance costs

19,872,747

'

'

'

'

'

'

'

'

6,958

'

'

'

'

19,865,789

'

'

'

'

'

'

'

'

'

Units sold in private placement, net of issuance costs (in shares)

'

'

'

'

'

'

'

'

'

6,957,914

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants issued

'

'

'

288,000

'

'

'

'

'

'

'

'

'

'

'

'

'

288,000

'

'

'

'

'

'

Conversion of notes payable upon event of merger

4,351,165

'

'

'

'

'

'

'

'

1,684

'

'

'

'

4,349,481

'

'

'

'

'

'

'

'

'

Conversion of notes payable upon event of merger (in shares)

'

'

'

'

'

'

'

'

'

1,684,085

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Note discount arising from beneficial conversion feature

483,463

'

'

'

'

'

'

'

'

'

'

'

'

'

483,463

'

'

'

'

'

'

'

'

'

Reverse merger transaction Elimination of accumulated deficit

-234,218

'

'

'

'

'

'

'

'

'

'

'

'

'

-234,218

'

'

'

'

'

'

'

'

'

Previously issued SMI stock

234,218

'

'

'

'

'

'

'

'

1,250

'

'

'

'

232,968

'

'

'

'

'

'

'

'

'

Previously issued SMI stock (in shares)

'

'

'

'

'

'

'

'

'

1,250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-10,302,795

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-10,302,795

Ending Balance at Dec. 31, 2007

15,199,932

'

'

'

'

'

'

'

'

24,100

'

'

'

'

28,070,642

'

'

'

'

'

'

'

'

-12,894,810

Ending Balance (in shares) at Dec. 31, 2007

'

'

'

'

'

'

'

'

'

24,099,716

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common shares

'

'

250,000

'

'

'

'

'

'

'

'

50

'

'

'

'

249,950

'

'

'

'

'

'

'

Issuance of common shares (in shares)

'

'

'

'

'

'

'

'

'

'

'

49,689

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

'

'

'

'

2,436,603

13,687

'

'

'

'

'

'

'

'

'

'

'

'

2,436,603

13,687

'

'

'

'

Warrants issued

'

'

'

'

'

'

334,992

'

'

'

'

'

'

'

'

'

'

'

'

'

334,992

'

'

'

Net loss

-13,131,596

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-13,131,596

Ending Balance at Dec. 31, 2008

5,103,618

'

'

'

'

'

'

'

'

24,150

'

'

'

'

31,105,874

'

'

'

'

'

'

'

'

-26,026,406

Ending Balance (in shares) at Dec. 31, 2008

'

'

'

'

'

'

'

'

'

24,149,405

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

'

'

'

'

1,772,597

473,584

'

'

'

'

'

'

'

'

'

'

'

'

1,772,597

473,584

'

'

'

'

Units sold in private placement, net of issuance costs

3,287,175

'

'

'

'

'

'

'

'

2,691

'

'

'

'

3,284,484

'

'

'

'

'

'

'

'

'

Units sold in private placement, net of issuance costs (in shares)

'

'

'

'

'

'

'

'

'

2,691,394

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock option and warrant exercises

217,473

'

'

'

'

'

'

'

'

245

'

'

'

'

217,228

'

'

'

'

'

'

'

'

'

Stock option and warrant exercises (in shares)

'

'

'

'

'

'

'

'

'

245,025

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-7,872,297

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-7,872,297

Ending Balance at Dec. 31, 2009

2,982,150

'

'

'

'

'

'

'

'

27,086

'

'

'

'

36,853,767

'

'

'

'

'

'

'

'

-33,898,703

Ending Balance (in shares) at Dec. 31, 2009

'

'

'

'

'

'

'

'

'

27,085,824

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

'

'

'

'

1,142,552

-19,249

'

'

'

'

'

'

'

'

'

'

'

'

1,142,552

-19,249

'

'

'

'

Units sold in private placement, net of issuance costs

4,516,699

'

'

'

'

'

'

'

'

7,475

'

'

'

'

4,509,224

'

'

'

'

'

'

'

'

'

Units sold in private placement, net of issuance costs (in shares)

'

'

'

'

'

'

'

'

'

7,475,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock option and warrant exercises

6,207

'

'

'

'

'

'

'

'

69

'

'

'

'

6,138

'

'

'

'

'

'

'

'

'

Stock option and warrant exercises (in shares)

'

'

'

'

'

'

'

'

'

68,970

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-6,031,491

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-6,031,491

Ending Balance at Dec. 31, 2010

2,596,868

'

'

'

'

'

'

'

'

34,630

'

'

'

'

42,492,432

'

'

'

'

'

'

'

'

-39,930,194

Ending Balance (in shares) at Dec. 31, 2010

'

'

'

'

'

'

'

'

'

34,629,794

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

'

'

'

'

785,587

20,740

'

'

'

'

'

'

'

'

'

'

'

'

785,587

20,740

'

'

'

'

Units sold in private placement, net of issuance costs

2,298,566

'

'

'

'

'

'

'

'

5,000

'

'

'

'

2,293,566

'

'

'

'

'

'

'

'

'

Units sold in private placement, net of issuance costs (in shares)

'

'

'

'

'

'

'

'

'

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock option and warrant exercises

13,748

'

'

'

'

'

'

'

'

82

'

'

'

'

13,666

'

'

'

'

'

'

'

'

'

Stock option and warrant exercises (in shares)

'

'

'

'

'

'

'

'

'

82,437

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-4,884,786

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-4,884,786

Ending Balance at Dec. 31, 2011

830,723

'

'

'

'

'

'

'

'

39,712

'

'

'

'

45,605,991

'

'

'

'

'

'

'

'

-44,814,980

Ending Balance (in shares) at Dec. 31, 2011

'

'

'

'

'

'

'

'

'

39,712,231

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

'

'

'

'

312,690

'

'

'

'

'

'

'

'

'

'

'

'

'

312,690

'

'

'

'

'

Units sold in private placement, net of issuance costs

1,194,207

'

'

'

'

'

'

'

'

3,350

'

'

'

'

1,190,857

'

'

'

'

'

'

'

'

'

Units sold in private placement, net of issuance costs (in shares)

'

'

'

'

'

'

'

'

'

3,350,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants issued

-611,896

'

'

'

'

'

'

'

'

'

'

'

'

'

-611,896

'

'

'

'

'

'

'

'

'

Net loss

-1,893,037

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-1,893,037

Ending Balance at Dec. 31, 2012

-167,313

'

'

'

'

'

'

'

'

43,062

'

'

'

'

46,497,642

'

'

'

'

'

'

'

'

-46,708,017

Ending Balance (in shares) at Dec. 31, 2012

'

'

'

'

'

'

'

'

'

43,062,231

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants exchanged for common stock

13,750

'

'

'

'

'

'

'

'

459

'

'

'

'

13,291

'

'

'

'

'

'

'

'

'

Warrants exchanged for common stock (in shares)

'

'

'

'

'

'

'

'

'

458,332

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

'

'

'

'

14,845

'

'

'

'

'

'

'

'

'

'

'

'

'

14,845

'

'

'

'

'

Net loss

-1,428,836

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-1,428,836

Ending Balance at Sep. 30, 2013

($1,567,554)

'

'

'

'

'

'

'

'

$43,521

'

'

'

'

$46,525,778

'

'

'

'

'

'

'

'

($48,136,853)

Ending Balance (in shares) at Sep. 30, 2013

'

'

'

'

'

'

'

'

'

43,520,563

'

'

'

'

'

'

'

'

'

'

'

'

'

'

CONDENSED_STATEMENT_OF_STOCKHO1

CONDENSED STATEMENT OF STOCKHOLDERS' (DEFICIT) EQUITY (Parenthetical) (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2007
Units sold in private placement, issuance costs	$145,793	$201,434	$715,801	$282,773	$102,000

CONDENSED_STATEMENTS_OF_CASH_F

CONDENSED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended		98 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Cash flows from operating activities	'	'	'
Net loss	($1,428,836)	($1,691,045)	($48,136,853)
Adjustment to reconcile net loss to net cash used in operating activities	'	'	'
Depreciation and amortization	1,353	4,806	328,257
Stock-based compensation	14,845	305,243	10,632,995
Conversion of warrants to common stock	13,750	0	13,750
Warrant liability	233,209	-431,046	-315,303
Write-off of intangible assets	0	0	106,830
Warrants issued in connection with note conversion	0	0	288,000
Note discount arising from beneficial conversion feature	0	0	483,463
Loss on disposal of assets	1,307	0	38,031
Noncash interest expense	147,696	0	498,861
Changes in operating assets and liabilities	'	'	'
Prepaid expenses and other current assets	86,937	115,456	-37,975
Other non-current assets	47,403	0	-4,535
Accounts payable	156,329	-227,787	339,245
Accrued expenses and other current liabilities	365,958	4,309	497,886
Due to related party	1,861	-30,826	18,000
Net cash used in operating activities	-358,188	-1,950,890	-35,249,348
Cash flows from investing activities	'	'	'
Purchase of property and equipment	0	0	-130,855
Proceeds from sale of assets	0	0	2,500
Cash paid for intangible assets	0	0	-345,591
Net cash used in investing activities	0	0	-473,946
Cash flows from financing activities	'	'	'
Proceeds from issuance of notes payable	382,500	0	5,882,500
Repayment of notes payable	0	0	-1,500,000
Proceeds from exercise of stock options and warrants	0	0	237,428
Proceeds from sale of common stock to founders	0	0	5,000
Proceeds from sale of common stock in private placement, net	0	1,194,207	31,169,394
Net cash provided by financing activities	382,500	1,194,207	35,794,322
Net (decrease) increase in cash and cash equivalents	24,312	-756,683	71,028
Cash and cash equivalents at beginning of period	46,716	1,039,190	0
Cash and cash equivalents at end of period	71,028	282,507	71,028
Supplemental schedule of cash flows information:	'	'	'
Cash paid for interest	0	0	150,000
Supplemental schedule of non-cash investing and financing activities:	'	'	'
Warrants issued in satisfaction of accrued liability	0	0	334,992
Warrants issued to placement agent and investors in connection with private placements	'	0	5,721,000
Warrants issued to investors in connection with registered direct offering	0	611,896	611,896
Conversion of notes payable and interest to common stock	0	0	4,351,165
Common shares of SMI issued in reverse merger transaction	$0	$0	$1,250

DESCRIPTION_OF_BUSINESS

DESCRIPTION OF BUSINESS	9 Months Ended
	Sep. 30, 2013
DESCRIPTION OF BUSINESS	'
	1. DESCRIPTION OF BUSINESS
	Nile Therapeutics, Inc. (“Nile” or the “Company”) engages in research and development of innovative products for the treatment of cardiovascular diseases. Nile’s lead compound is cenderitide, a chimeric natriuretic peptide currently in development for the treatment of heart failure patients in the post-acute period. The Company is also developing CU-NP, a pre-clinical rationally designed natriuretic peptide that consists of amino acid chains identical to those produced by the human body, specifically the ring structure of C-type Natriuretic Peptide (“CNP”) and the N- and C-termini of Urodilatin (“URO”).
	The Company was incorporated in the State of Nevada on June 17, 1996 and reincorporated in Delaware on February 9, 2007, at which time its name was SMI Products, Inc. (“SMI”). On September 17, 2007, the Company completed a merger transaction whereby Nile Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of SMI, merged with and into Nile Therapeutics, Inc., a privately held Delaware corporation (“Old Nile”), with Old Nile becoming a wholly-owned subsidiary of SMI. Immediately following the merger described above, Old Nile was merged with and into the Company, with the Company remaining as the surviving corporation to that merger. In connection with that short-form merger, the Company changed its name to “Nile Therapeutics, Inc.” All costs incurred in connection with the SMI merger transactions have been expensed. Upon completion of these merger transactions, the Company adopted Old Nile’s business plan.
	On July 7, 2013, the Company entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Capricor, Inc. (“Capricor”), a privately held company incorporated in Delaware, and Bovet Merger Corp., a Delaware corporation and a wholly-owned subsidiary of the Company (“Merger Sub”), pursuant to which Merger Sub, subject to certain conditions contained in the Merger Agreement, will merge with and into Capricor and Capricor will become a wholly-owned subsidiary of the Company (the “Merger”). The Merger Agreement was amended on September 27, 2013.  Upon completion of the Merger, each outstanding share of Capricor common stock, and each security convertible into Capricor common stock, will automatically convert into the right to receive a number of shares of the Company’s common stock, or, as applicable, securities convertible into the Company’s common stock, such that, after giving effect to the Merger, the holders of Capricor capital stock immediately prior to the Merger will hold, in the aggregate, 90% of the total number of shares of the Company’s common stock on a fully-diluted basis. Capricor is a company whose mission is to improve the treatment of heart disease by commercializing cardiac stem cell therapies for patients.
	The Merger Agreement contains customary representations and warranties by the Company and Capricor with respect to their businesses and the transactions contemplated by the Merger Agreement. Closing of the Merger is conditioned on, among other things, accuracy of such representations and warranties, approval of the Merger Agreement by the requisite number of Capricor’s stockholders, conversion of each share of Capricor preferred stock into Capricor common stock, and stockholder approval of an amendment to the Company’s Certificate of Incorporation authorizing a reverse split of the Company’s common stock at a ratio not to exceed 1-for-100. In addition, the closing of the Merger is conditioned on the Company amending its technology license agreement with the Mayo Foundation and evidence of payment or other satisfaction in full (including releases) of accrued liabilities and obligations of the Company (with the exception of obligations not to exceed the aggregate amount of $100,000, which may remain outstanding through the effective time of the Merger). The Merger Agreement may be terminated for certain reasons, including by either party if the closing thereof does not occur prior to November 15, 2013. The Merger Agreement also contains other customary terms and provisions as are common in similar agreements.
	The Company’s executive officers will resign and will be replaced by the current officers of Capricor. Following completion of the planned merger, Capricor will continue its focus on developing its product pipeline and the Company expects that the combined company will also eventually continue the development of cenderitide and CU-NP. See Note 3, below.

BASIS_OF_PRESENTATION_AND_SUMM

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2013
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	2. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	The Company is a development stage enterprise since it has not yet generated any revenue from the sale of products and, through September 30, 2013, its efforts have been principally devoted to developing its licensed technologies, and raising capital. Accordingly, the accompanying condensed financial statements have been prepared in accordance with the provisions of Accounting Standards Codification (“ASC”) 915, “Development Stage Entities.”
	The accompanying unaudited Condensed Financial Statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q adopted under the Securities Exchange Act of 1934, as amended. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America (“GAAP”) for complete financial statements. In the opinion of Nile’s management, the accompanying Condensed Financial Statements contain all adjustments (consisting of normal recurring accruals and adjustments) necessary to present fairly the financial position, results of operations and cash flows of the Company at the dates and for the periods indicated. The interim results for the period ended September 30, 2013 are not necessarily indicative of results for the full 2013 fiscal year or any other future interim periods. Because the 2007 merger with SMI was accounted for as a reverse acquisition under generally accepted accounting principles, the financial statements for periods prior to September 17, 2007 reflect only the operations of Old Nile.
	These unaudited Condensed Financial Statements have been prepared by management and should be read in conjunction with the Financial Statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012 filed with the Securities and Exchange Commission.
	The preparation of financial statements in conformity with GAAP requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting periods. Estimates and assumptions principally relate to services performed by third parties but not yet invoiced, estimates of the fair value and forfeiture rates of stock options issued to employees and consultants, and estimates of the probability and potential magnitude of contingent liabilities. Actual results could differ from those estimates.
	Collaboration Income
	In February 2011, the Company entered into a collaboration agreement whereby the Company was reimbursed for work performed on behalf of the collaborator upon the achievement of certain milestones. The Company recorded all of these expenses as research and development expenses and the reimbursements upon the achievement of the milestones as income (Note 5).
	The Company recognizes milestone payments as income upon achievement of the milestone only if (1) the milestone payment is non-refundable, (2) substantive effort is involved in achieving the milestone, (3) the amount of the milestone is reasonable in relation to the effort expended or the risk associated with achievement of the milestone and (4) the milestone is at risk for both parties. If any of these conditions are not met, the Company defers the milestone payment and recognizes it as income over the remaining estimated period of performance under the contract as the Company completes its performance obligations.
	Research and Development
	Research and development costs are charged to expense as incurred. Research and development includes employee costs, fees associated with operational consultants, contract clinical research organizations, contract manufacturing organizations, clinical site fees, contract laboratory research organizations, contract central testing laboratories, licensing activities, and allocated office, insurance, depreciation, and facilities expenses. The Company accrues for costs incurred as the services are being provided by monitoring the status of the trial and the invoices received from its external service providers. The Company adjusts its accruals in the period when actual costs become known. Costs related to the acquisition of technology rights for which development work is still in process are charged to operations as incurred and considered a component of research and development costs.
	Fair Value of Financial Instruments
	The Company measures fair value in accordance with generally accepted accounting principles. Fair value measurements are applied under other accounting pronouncements that require or permit fair value measurements. Financial instruments included in the Company’s balance sheets consist of cash and cash equivalents, accounts payable, accrued expenses, due to related parties, and warrant liability. The carrying amounts of these instruments reasonably approximate their fair values due to their short-term maturities.
	Warrant Liability
	The Company accounts for the warrants issued in connection with the March 2013 convertible note issuance (Note 6) and the April 2012 financing (Note 8) in accordance with the guidance on Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, which provides that the Company classifies the warrant instrument as a liability at its fair value and adjust the instrument to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized as a component of other income or expense. The fair value of warrants issued by the Company, in connection with the April 2012 financing, have been estimated by management using a binomial options pricing model. The binomial option pricing model is a generally accepted valuation model used to generate a defined number of stock price paths in order to develop a reasonable estimate of the range of the Company’s future expected stock prices, and their resulting probabilistic valuation. In connection with the March 2013 convertible note issuance, the Company estimated the fair value of the embedded derivative warrant liability by using the Black-Scholes option-pricing model.

LIQUIDITY_CAPITAL_RESOURCES_AN

LIQUIDITY, CAPITAL RESOURCES AND MANAGEMENT'S PLANS	9 Months Ended
	Sep. 30, 2013
LIQUIDITY, CAPITAL RESOURCES AND MANAGEMENT'S PLANS	'
	3. LIQUIDITY, CAPITAL RESOURCES AND MANAGEMENT’S PLANS
	As discussed above under Note 1, on July 7, 2013, the Company entered into a merger agreement with Capricor. Following completion of the planned merger, the Company anticipates that the combined company, under the leadership of Capricor’s management, will eventually continue the development of cenderitide and CU-NP (Note 5), in addition to Capricor’s current research and development programs.
	The Company does do not have the capital resources available to continue the development of our product development programs or to otherwise remain in business. For more than 12 months, we have sought either additional financing to fund such activities or a collaboration or other strategic agreement with another company that would provide the capital needed to fund further development of the Company’s product candidates. Prior to our entry into the Capricor merger agreement, the Company had been unsuccessful in securing such additional capital. The planned merger with Capricor is subject to several conditions, including the approval of stockholders of a reverse split of the Company’s common stock at a ratio not to exceed 1-for-100. If such conditions are not satisfied, the Company may be unable to complete the planned merger. In that case, the Company would be forced to liquidate.
	The Company has experienced net losses since its inception and has an accumulated deficit of approximately $48.1 million at September 30, 2013. Cash resources as of September 30, 2013 were approximately $0.1 million, compared to $0.05 million as of December 31, 2012. Based on its currently available cash resources, including the proceeds from the additional Notes (see Note 12), the Company believes that it only has sufficient capital to fund its minimal operating expenses until the middle of the fourth quarter of 2013. The Company will need to raise additional capital to fund any clinical development and to otherwise continue operations beyond the middle of the fourth quarter of 2013. Additionally, the Company will need substantial additional financing in the future until it can achieve profitability, if ever. The Company’s continued operations will depend on its ability to raise additional funds through various potential sources, such as equity and debt financing, or to license its product candidates to another pharmaceutical company. The Company will continue to fund operations from cash on hand and through sources of capital similar to those previously described. The Company cannot assure that it will be able to secure such additional financing, or if available, that it will be sufficient to meet its needs.
	These factors raise substantial doubt about the Company's ability to continue as a going concern. The Company’s Condensed Financial Statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The financial statements do not include any adjustments that might result from the inability of the Company to continue as a going concern.

BASIC_AND_DILUTED_LOSS_PER_SHA

BASIC AND DILUTED LOSS PER SHARE	9 Months Ended
	Sep. 30, 2013
BASIC AND DILUTED LOSS PER SHARE	'
	4. BASIC AND DILUTED LOSS PER SHARE
	Basic loss per share is computed by dividing the loss available to common shareholders by the weighted-average number of common shares outstanding. Diluted loss per share is computed similarly to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.
	For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive. There are no potentially dilutive securities as of September 30, 2013 and 2012.
	For the three and nine months ended September 30, 2013 and 2012, warrants and options to purchase 9,861,400 and 16,762,331 shares, respectively, have been excluded from the computation of potentially dilutive securities, respectively, as their exercise prices are greater than the average market price per common share for the periods ended September 30, 2013 and September 30, 2012, respectively.

INTANGIBLE_ASSETS_AND_INTELLEC

INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY	9 Months Ended
	Sep. 30, 2013
INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY	'
	5. INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY
	License Agreements
	Cenderitide
	On January 20, 2006, the Company entered into an exclusive, worldwide, royalty-bearing license agreement, or the Cenderitide License Agreement, with Mayo Foundation for Medical Education and Research (“Mayo”) for the rights to issued patents, patent applications and know-how relating to the use of cenderitide in all therapeutic indications.  The Company was also entitled to rights to improvements to cenderitide that arose out of the laboratory of Dr. John Burnett, the co-inventor of cenderitide, until January 19, 2009.
	Under the terms of the Cenderitide License Agreement, the Company paid Mayo an up-front cash payment, reimbursed it for past patent expenses and issued to Mayo 1,379,419 shares of common stock. Additionally, the Company agreed to make contingent cash payments up to an aggregate of $31.9 million upon successful completion of specified clinical and regulatory milestones relating to cenderitide. This aggregate amount is subject to increase upon the receipt of regulatory approval for each additional indication of cenderitide as well as for additional compounds or analogues contained in the intellectual property. In July 2008, the Company made a milestone payment of $400,000 to Mayo upon the dosing of the first patient in a Phase 2 trial.  Based on the current stage of research the Company does not expect to make any milestone payments for the year ending December 31, 2013. Pursuant to the Cenderitide License Agreement, the Company will pay Mayo an annual maintenance fee and a percentage of net sales of licensed products, as well as $50,000 per year for the consulting services of Dr. Burnett while serving as chairman of the Company’s Scientific Advisory Board.
	In addition to the potential milestone payments discussed above, the Cenderitide License Agreement requires the Company to issue shares of common stock to Mayo for an equivalent dollar amount of grants received in excess of $300,000, but not to exceed $575,000. For the period from August 1, 2005 (inception) through September 30, 2013, the Company received $482,235 in grant income for which it has issued to Mayo 63,478 shares of common stock. No such grant income has been received or shares issued since the year ended December 31, 2008.
	The Cenderitide License Agreement, unless earlier terminated, will continue in full force and effect until January 20, 2026. However, to the extent any patent covered by the license is issued with an expiration date beyond January 20, 2026, the term of the agreement will continue until such expiration date. Mayo may terminate the agreement earlier (i) for the Company’s material breach of the agreement that remains uncured after 90 days’ written notice, (ii) the Company’s insolvency or bankruptcy, or (iii) if the Company challenges the validity or enforceability of any of the patents in any manner. The Company may terminate the agreement without cause upon 90 days’ written notice.
	As of September 30, 2013, the Company was not in compliance with several terms of the Cenderitide License Agreement, including, but not limited to, provisions requiring the Company to pay the Mayo Foundation an annual maintenance fee and actively pursue the development of cenderitide. The Company is in discussions with the Mayo Foundation to amend the agreement, but the Company cannot guarantee that it will be able to reach an agreement with Mayo that allows the Company to maintain its rights to cenderitide. The Company currently owes Mayo approximately $154,100 in fees and expense reimbursements related to the Cenderitide License Agreement, all of which is included in accounts payable. The Company is currently negotiating with Mayo to amend its license agreements relating to cenderitide and CU-NP in order to satisfy and/or modify the Company’s outstanding obligations to Mayo. The Company anticipates that it will conclude such negotiations prior to completing its planned merger with Capricor.
	CU-NP
	On June 13, 2008, the Company entered into an exclusive, worldwide, royalty-bearing license agreement, or the CU-NP License Agreement, with Mayo for the rights to intellectual property and to develop commercially CU-NP for all therapeutic indications. The Company was also entitled to rights to improvements to CU-NP that arose out of the laboratory of Dr. John Burnett and Dr. Candace Lee, the inventors of CU-NP, until June 12, 2011.
	Under the terms of the CU-NP License Agreement, the Company made an up-front cash payment to Mayo and agreed to make future contingent cash payments up to an aggregate of $24.3 million upon achievement of specific clinical and regulatory milestones relating to CU-NP, including a milestone payment due in connection with the initiation of the first Phase 2 clinical trial of the licensed product. This aggregate amount of $24.3 million is subject to increase upon the receipt of regulatory approval for each additional indication of CU-NP, as well as for additional compounds or analogues contained in the intellectual property. Based on the current stage of research the Company does not expect to make any milestone payments for the year ending December 31, 2013. Pursuant to the agreement, the Company must also pay Mayo an annual maintenance fee and a percentage of net sales of licensed products.
	In addition to these cash payments payable with respect to the CU-NP License Agreement, the Company also agreed to issue shares of its common stock and warrants to Mayo. In June 2008, the Company issued 49,689 shares of common stock to Mayo having a fair market value as of June 13, 2008 equal to $250,000. This amount has been recorded in research and development expenses in the accompanying Condensed Statements of Operations.
	The CU-NP License Agreement, unless earlier terminated, will continue in full force and effect until June 13, 2028. However, to the extent any patent covered by the license is issued with an expiration date beyond June 13, 2028, the term of the agreement will continue until such expiration date. Mayo may terminate the agreement earlier (i) for the Company’s material breach of the agreement that remains uncured after 90 days written notice, (ii) the Company’s insolvency or bankruptcy, (iii) if the Company challenges the validity or enforceability of any of the patents in any manner, or (iv) upon receipt of notice from the Company that it has terminated all development efforts under the agreement. The Company may terminate the agreement without cause upon 90 days’ written notice.
	As of September 30, 2013, the Company was not in compliance with several terms of the CU-NP License Agreement, including, but not limited to, provisions requiring the Company to pay the Mayo Foundation an annual maintenance fee and actively pursue the development of CU-NP. The Company is in discussions with the Mayo Foundation to amend the agreement, but the Company cannot guarantee that it will be able to reach an agreement with Mayo that allows the Company to maintain its rights to CU-NP. As of September 30, 2013, the Company owed Mayo approximately $39,300 in fees and expense reimbursements related to the CU-NP License Agreement, all of which is included in accounts payable.
	Collaboration Agreement
	In February 2011, the Company entered into a Clinical Trial Funding Agreement with Medtronic, Inc. Pursuant to the agreement, Medtronic provided the funding and equipment necessary for the Company to conduct a Phase 1 clinical trial to assess the pharmacokinetics and pharmacodynamics of cenderitide when delivered to heart failure patients through continuous subcutaneous infusion using Medtronic’s diabetes pump technology.
	Under the agreement, the Company agreed not to enter into an agreement with a third party to develop or commercialize cenderitide or any drug/device combination developed under the agreement until the earlier of: (i) three months following delivery to Medtronic of a final database with respect to the Phase 1 trial; and (ii) 15 months after the date of the agreement. The final database was delivered to Medtronic on November 19, 2011.
	The agreement also provided that intellectual property conceived in or otherwise resulting from the performance of the Phase 1 clinical trial shall be jointly owned by Nile and Medtronic (the “Joint Intellectual Property”), and that Nile shall pay royalties to Medtronic based on the net sales of any Nile product, the manufacture, use or sale of which is covered or claimed in one or more issued patents constituting Joint Intellectual Property.  The agreement further provided that, if the parties fail to enter into a definitive commercial license agreement with respect to cenderitide, then each party shall have a right of first negotiation to license exclusive rights to any Joint Intellectual Property. As of September 30, 2013, three filed patent applications are considered Joint Intellectual Property.
	Pursuant to its terms, the agreement expired in February 2012, following the completion of the Phase 1 clinical trial and the delivery of data and reports related to the study. The Company received the final reimbursement of $195,500 in February 2012 and a total of $1,550,000 over the life of the agreement. All amounts are recorded as collaboration income in the Company’s Condensed Statement of Operations.

CONVERTIBLE_NOTES_PAYABLE

CONVERTIBLE NOTES PAYABLE	9 Months Ended
	Sep. 30, 2013
CONVERTIBLE NOTES PAYABLE	'
	6. CONVERTIBLE NOTES PAYABLE
	On March 15, 2013, the Company entered into a convertible note purchase agreement with certain accredited investors pursuant to which the Company agreed to sell an aggregate principal amount of up to $500,000 of secured convertible promissory notes (the “2013 Notes”) for an aggregate original issue price of $425,000, representing a 15% original issue discount. The closing of the private placement also occurred on March 15, 2013, and resulted in the sale of the 2013 Notes in the aggregate principal amount of $450,000 for an aggregate original issue price of $382,500. The original issue discount is $67,500 and is being amortized to interest expense over the term of the 2013 Notes. As of September 30, 2013, the unamortized balance of this original issue discount is $30,699.
	The 2013 Notes, which have a maturity date of March 15, 2014, do not bear interest and may be prepaid without penalty upon 30 days’ written notice, on the terms set forth in the Notes. The 2013 Notes are secured by a blanket lien on our assets pursuant to a security agreement dated March 15, 2013.
	The 2013 Notes contain an optional conversion feature that enables the Holder to convert all outstanding shares into shares of the Company's common stock at a conversion price per share equal to the average daily Closing Price over the ten consecutive trading days preceding the date of such prepayment notice. The optional conversion feature goes into effect only if the Company chooses to prepay the Notes in whole or in part without penalty upon 30 days' prior written notice to the Holder (and conversion must occur within this 30 day period).
	On September 27, 2013, the Company and the holders of the Notes entered into an amendment to the Notes, which provided, among other things, that upon a Change of Control as described above, the conversion price applicable to the Notes and the exercise price applicable to the warrants issuable upon a Change of Control will be equal to the average dollar volume weighted average price ("VWAP") of the Company's common stock for each trading day during the period from July 8, 2013 to September 30, 2013. The average VWAP during such period is approximately $0.045 per share. Additionally, pursuant to the amendment, upon a conversion of the Notes in connection with a Change of Control, the holders confirmed that all obligations under the Notes would be deemed satisfied in full and released the Company from any claims relating to the Notes.
	Pursuant to the terms of the 2013 Notes, upon a Change of Control (as defined in the 2013 Notes) in which either (i) the outstanding shares of the Company’s common stock are exchanged for securities of another corporation, or (ii) the Company issues shares of common stock, with no securities or other consideration paid or payable to holders of our common stock (e.g., a merger transaction in which the Company acquires another corporation in exchange for shares of our common stock), then (A) the entire unpaid principal under the applicable 2013 Note shall automatically convert, as of immediately prior to the effective time of the Change of Control, into shares of the Company’s common stock at a conversion price per share equal to approximately $0.045 on the effective date of the Change of Control, and (B) the Company shall also issue to each 2013 Note holder a five-year warrant entitling the holder to purchase, at an exercise price equal to approximately $0.045, that number of shares of our common stock obtained by dividing (a) the sum of the outstanding principal under the applicable Note by (b) approximately $0.045. Upon a Change of Control other than as described in the preceding sentence, the Company shall pay to each 2013 Note holder an amount in cash equal to 175% of the principal amount then outstanding under the applicable Note. Upon payment of such amount to the 2013 Note holders, all of the obligations under the Notes shall be deemed paid and satisfied in full.
	The warrants issuable upon a Change of Control are considered an embedded derivative and were bifurcated from the notes and accounted for separately at fair value. The fair value of the warrants was $203,400 on March 15, 2013, the date of issuance, and were recorded as additional debt discount (Note 7). The Company will revalue the warrants on a quarterly basis until the warrants are issued or the 2013 Notes are repaid in full. As of September 30, 2013, the fair value of the warrants was $393,200. Following the entry into, and subsequent amendment of the merger agreement with Capricor (Note 1), management have estimated the probability of issuance to be 95% as of September 30, 2013. Management used the following assumptions for the Black-Scholes valuation of the 2013 Notes on March 15, 2013 and September 30, 2013:
		March 15, 2013			September 30, 2013
	Stock Price :	$	0.09		$	0.05
	Strike Price :	$	0.09		$	0.05
	Risk-free Rate:		0.84	%		1.39	%
	Volatility		148	%		153	%
	Term		5 years			5 years
	Probability of issuance:		50	%		95	%
	The discount is being amortized to interest expense over the one year term of the 2013 Notes. As of September 30, 2013, the unamortized balance of this note discount is $92,505.

FAIR_VALUE_OF_FINANCIAL_INSTRU

FAIR VALUE OF FINANCIAL INSTRUMENTS	9 Months Ended
	Sep. 30, 2013
FAIR VALUE OF FINANCIAL INSTRUMENTS	'
	7. FAIR VALUE OF FINANCIAL INSTRUMENTS
	The Company defines fair value as the amount at which an asset (or liability) could be bought (or incurred) or sold (or settled) in a current transaction between willing parties, that is, other than in a forced or liquidation sale. The fair value estimates presented in the table below are based on information available to the Company as of September 30, 2013.
	The accounting standard regarding fair value measurements discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The standard utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:
		•	Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
		•	Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
		•	Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions.
	The Company has determined the fair value of certain liabilities using the market approach. The following table presents the Company’s fair value hierarchy for these assets measured at fair value on a recurring basis as of September 30, 2013:
					Quoted Market				Significant
			Fair Value		Prices in Active		Significant Other		Unobservable
			September 30,		Markets		Observable Inputs		Inputs
			2013		(Level 1)		(Level 2)		(Level 3)
	Liabilities
	Warrant liability - April 2012 issuance		$	106,793	$	-	$	-	$	106,793
	Warrant liability - 2013 Notes			393,200		-		-		393,200
	Total		$	499,993	$	-	$	-	$	499,993
	The fair value of the warrant liability relating to the 2013 Notes (Note 6) was estimated by management using the Black-Scholes option-pricing model. The changes in the fair value of the warrant liability are recorded in other income (expense) on the Condensed Statements of Operations.
	The fair value of the warrant liability relating to the warrants issued in conjunction with the April 2012 financing (Note 8b) was estimated by management using a binomial option pricing model. The binomial option pricing model is a generally accepted valuation model used to generate a defined number of stock price paths in order to develop a reasonable estimate of the range of the Company’s future expected stock prices, and their resulting probabilistic valuation. The changes in the fair value of the warrant liability are recorded in other income (expense) on the Condensed Statements of Operations.
	The following table provides a summary of changes in fair value of the Company’s liabilities, as well as the portion of losses included in income attributable to unrealized appreciation that relate to those liabilities held at September 30, 2013:
			Fair Value
			Measurements Using
			Significant
			Unobservable Inputs
			(Level 3)
			Warrant Liability
	Balance at January 1, 2013		$	63,384
	Purchases, sales and settlements:
	Derivatives issued			203,400
	Total gains or losses
	Unrealized appreciation			233,209
	Balance at September 30, 2013		$	499,993

STOCKHOLDERS_DEFICIT

STOCKHOLDERS' DEFICIT

9 Months Ended

Sep. 30, 2013

STOCKHOLDERS' EQUITY

'

8. STOCKHOLDERS’ DEFICIT

On July 7, 2013, the Company entered into an Agreement and Plan of Merger and Reorganization with Capricor, Inc., a Delaware corporation (“Capricor”), and Bovet Merger Corp., a wholly-owned subsidiary of the Company. Pursuant to this agreement, Bovet Merger Corp. will merge with and into Capricor, with Capricor remaining as the surviving corporation and a wholly-owned subsidiary of the Company. In connection with this merger transaction, the current stockholders of Capricor will receive in exchange for their shares of Capricor stock a number of shares of the Company’s common stock such that, following the merger, the former Capricor stockholders will hold 90% of the outstanding shares of the Company’s common stock on a fully-diluted basis

(a) Common Stock

On April 4, 2012, the Company closed an offering with certain purchasers pursuant to which it sold an aggregate of 3,350,000 shares of the Company’s common stock to such purchasers for a purchase price of $0.40 per share. In addition, for each share purchased, each purchaser also received three-fourths of a five-year warrant to purchase an additional share of common stock at an exercise price of $0.50 per share, which resulted in the issuance of warrants to purchase an aggregate of 2,512,500 shares of the Company’s common stock. The warrants contain non-standard anti-dilution features (Note 8b) and as result will be classified as a liability on the Company’s Condensed Balance Sheet.

The total gross proceeds from the offering were $1.34 million, before deducting selling commissions and other offering expenses of approximately $0.14 million. In connection with the offering, the Company engaged Roth Capital Partners, LLC, or Roth, to serve as placement agent. Pursuant to the terms of the placement agent agreement, the Company paid Roth a cash fee equal to seven percent of the gross proceeds received by the Company, or approximately $0.11 million, plus a non-accountable expense allowance of $35,000. Richard B. Brewer, the Company’s former Executive Chairman, Joshua A. Kazam, the Company’s former President and Chief Executive Officer and a director, Daron Evans, the Company’s Chief Financial Officer, and Hsiao Lieu, M.D., the Company’s former Executive VP of Clinical Development, participated in the offering on the same terms as the unaffiliated purchasers, and collectively purchased 275,000 shares of common stock and warrants to purchase 206,250 shares of common stock for an aggregate purchase price of $110,000.

On August 1, 2013, the Company entered into warrant exchange agreements with each holder of the warrants to purchase an aggregate of 2,750,000 shares of common stock that were issued in connection with the Company’s June 2011 private placement. Pursuant to such agreements, each such holder received 0.1667 shares of the Company’s common stock for each warrant share purchasable under the warrants held by such holder. The Company issued total number of 458,332 shares of its common stock pursuant to the warrant exchange agreements with a fair value of $13,750.  The Company recorded the fair value of the shares as additional expense in the condensed statements of operations.

(b) Warrants

In connection with the April 2012 financing, as discussed above, the Company issued a total of 2,512,500 warrants, each of which has a term of five years and represents the right to purchase one share of the Company’s common stock at an exercise price of $0.50 per share. The warrants contain non-standard anti-dilution features, such that, in the event the Company issues common shares at a price below the current exercise price of the warrants, the exercise price of the warrants will be adjusted based on the lower issuance price. Because of this anti-dilution provision and the inherent uncertainty as to the probability of future common share issuances, the Black-Scholes option pricing model the Company uses for valuing stock options could not be used. Management used a binomial option pricing model to determine the warrant liability to be approximately $0.6 million on the date of issuance and $0.1 million at September 30, 2013. The binomial option pricing model (Note 7) is used for the valuation of the warrant liability, which will be revised on a quarterly basis until the warrants are exercised or they expire with the changes in fair value recorded in other income (expense) on the Condensed Statements of Operations.

Significant assumptions used at September 30, 2013 for the warrants included a weighted average term of 3.50 years, volatility of 153%, and a risk-free interest rate of 1.39%.

The 2012 warrants provide that, upon certain fundamental corporate transactions, such as a merger transaction involving the Company, the warrant holders can elect to receive a cash amount equal to the Black-Scholes value of the warrant, as described in such warrants.  As of September 30, 2013, the aggregate Black-Scholes value of such warrants was approximately $110,550.  Following the completion of the quarter ended September 30, 2013, the Company and holders of 2012 warrants to purchase 2,503,125 shares entered into agreements pursuant to which such holders agreed to receive, upon the completion of the Merger with Capricor, an equal number of shares of common stock in exchange for the surrender and cancellation of their warrants, including cancellation of their right to receive the cash payment of the Black-Scholes value of the warrants upon completion of the Merger.

In connection with the 2011 Offering, the Company issued a total of 2,500,000 Warrants, each of which has a term of five years and represents the right to purchase one share of the Company’s common stock at an exercise price of $0.60 per share. In addition, the Company issued the Placement Agents a five-year warrant to purchase 250,000 shares of the Company’s common stock at an exercise price of $0.60 per share. As discussed above, as a result of the exchange agreement, all of the warrants issued in connection with the 2011 offering have been cancelled.

At September 30, 2013, the Company had outstanding warrants to purchase an aggregate of 2,904,695 shares of its common stock that were originally issued on July 15, 2009 in connection with the Company’s private placement of common stock and warrants (the “2009 Warrants”).  The 2009 Warrants have exercise prices ranging from $1.25 to $2.28 per share. On November 13, 2013, the Company entered into warrant exchange agreements with holders of 2009 Warrants to purchase 1,484,695 shares.  Under the terms of these agreements, the Company issued to such holders approximately 0.01102 shares of common stock for each share of common stock underlying their 2009 Warrants for a total issuance of 16,360 shares of common stock. Upon such issuance, all rights of such holders under their 2009 Warrants terminated.

Below is a table that summarizes all outstanding warrants to purchase shares of the Company’s common stock as of September 30, 2013.

Weighted

Exercise

Average

Grant

Warrants

Price

Exercise

Expiration

Warrants

Date

Issued

Range

Price

Date

Exercised

Outstanding

7/15/09

2,909,695

$

1.25-2.28

$

1.64

7/14/14

5,000

2,904,695

4/21/10

2,632,500

$

0.94

$

0.94

4/20/15

-

2,632,500

4/4/12

2,512,500

$

0.5

$

0.5

4/3/17

-

2,512,500

8,054,695

$

1.13

5,000

8,049,695

STOCK_OPTION_PLAN

STOCK OPTION PLAN	9 Months Ended
	Sep. 30, 2013
STOCK OPTION PLAN	'
	9. STOCK OPTION PLAN
	The Company’s Amended and Restated 2005 Stock Option Plan (the “Plan”) was initially adopted by the Board of Directors on August 10, 2005. The Plan authorized a total of 2,000,000 shares of common stock for issuance. On September 17, 2007, pursuant to the merger with SMI, the Plan was amended and each share of common stock then subject to the Plan was substituted with 2.758838 shares of common stock, resulting in an aggregate of 5,517,676 shares available under the Plan. On July 26, 2010, the Company’s stockholders approved an amendment to the Plan increasing the total number of shares authorized for issuance thereunder to 9,500,000. Under the Plan, incentives may be granted to officers, employees, directors, consultants, and advisors. Incentives under the Plan may be granted in any one or a combination of the following forms: (a) incentive stock options and non-statutory stock options, (b) stock appreciation rights, (c) stock awards, (d) restricted stock and (e) performance shares. The Plan is administered by the Board of Directors, or a committee appointed by the Board, which determines the recipients and types of awards to be granted, as well as the number of shares subject to the awards, the exercise price and the vesting schedule. The term of stock options granted under the Plan cannot exceed ten years. Currently, stock options are granted with an exercise price equal to the closing price of the Company’s common stock on the date of grant, and generally vest over a period of one to four years.
	For the three and nine months ended September 30, 2013 and September 30, 2012, the Company did not issue any employee stock options.
	A summary of the status of the options issued under the Plan at September 30, 2013, and information with respect to the changes in options outstanding is as follows:
			Shares			Outstanding			Weighted-			Aggregate
			Available for			Stock			Average			Intrinsic
			Grant			Options			Exercise Price			Value
	Balance at January 1, 2013			4,537,522			4,571,046		$	1.24
	Options granted under the Plan			-			-		$	-
	Options exercised			-			-		$	-
	Options forfeited			2,759,341			-2,759,341		$	1.38
	Balance at September 30, 2013			7,296,863			1,811,705		$	1.02		$	-
	Exercisable at September 30, 2013						1,811,705		$	1.02		$	-
	The following table summarizes information about stock options outstanding at September 30, 2013:
				Outstanding									Exercisable
							Weighted-
							Average									Weighted-
	Range of						Remaining			Weighted-Average						Average
	Exercise Prices			Shares			Contractual Life			Exercise Price			Total Shares			Exercise Price
	$	0.09 to $0.57			696,533			3.38		$	0.45			696,533		$	0.45
	$	0.68 to $0.93			835,172			2.67		$	0.85			835,172		$	0.85
	$	1.77 to $4.50			280,000			5.17		$	2.94			280,000		$	2.94
		Total			1,811,705			3.33		$	1.02			1,811,705		$	1.02
	Share-based compensation is recognized only for those awards that are ultimately expected to vest; therefore, the Company has applied an estimated forfeiture rate to unvested awards for the purpose of calculating compensation cost. These estimates will be revised, if necessary, in future periods if actual forfeitures differ from estimates. Changes in forfeiture estimates impact compensation cost in the period in which the change in estimate occurs.
	Employee stock-based compensation costs for the three and nine months ended September 30, 2013 and 2012 and for the cumulative period from August 1, 2005 (inception) through September 30, 2013 are as follows:
															Period from
															August 1, 2005
			Three months ended						Nine months ended						(inception)
			September 30,						September 30,						through September 30,
			2013			2012			2013			2012			2013
	General and administrative		$	-		$	51,210			14,845		$	237,957		$	6,822,795
	Research and development			-			-			-			67,286			1,551,203
	Total		$	-		$	51,210			14,845		$	305,243		$	8,373,998
	The fair value of shares vested under the Plan for the three and nine months ended September 30, 2013 and 2012 and for the period from August 1, 2005 (inception) through September 30, 2013 were $0, $14,862, $217,101, $625,961 and $7,620,918 respectively.
	At September 30, 2013, there were no unrecognized estimated employee (including directors) compensation costs related to stock options. All employee options outstanding were fully vested as of September 30, 2013.
	Common stock, stock options or other equity instruments issued to non-employees (including consultants and all members of the Company’s Scientific Advisory Board) as consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued (unless the fair value of the consideration received can be more reliably measured). The fair value of any options issued to non-employees is recorded as expense over the applicable service periods.
	The Company did not incur stock-based compensation costs for services by non-employees for the three and nine months ended September 30, 2013 and 2012, and has expensed a total of $498,095 for the cumulative period from August 1, 2005 (inception) through September 30, 2013. These amounts were included in research and development and general and administrative expenses in the accompanying Condensed Statements of Operations. As of September 30, 2013 all non-employee based options outstanding were fully vested.
	On August 9, 2013, holders of options to purchase, at exercise prices ranging from $0.301 to $4.50 per share, an aggregate of 1,774,341 shares of the Company’s common stock pursuant to the Plan agreed to terminate all of their rights in such stock options effective immediately prior to the effective time of the Company’s planned merger with Capricor. Such holders, all of whom are directors or officers of the Company, did not receive any consideration for such agreements.

RELATED_PARTIES

RELATED PARTIES	9 Months Ended
	Sep. 30, 2013
RELATED PARTIES	'
	10. RELATED PARTIES
	On June 24, 2009, the Company entered into a services agreement with Two River Consulting, LLC (“TRC”) to provide various clinical development, operational and administrative services to the Company, including the part-time services of Joshua A. Kazam as the Company’s President and Chief Executive Officer, for a period of one year.  Mr. Kazam and Arie S. Belldegrun are each directors of the Company and partners of TRC.  David M. Tanen, who served as the Company’s Secretary and director until his resignation from both positions on September 24, 2009, is also a partner of TRC. The terms of the services agreement were reviewed and approved by a special committee of the Company’s Board of Directors consisting of independent directors (the “Special Committee”).  None of the members of the Special Committee had any interest in TRC or the services agreement.  As compensation for the services contemplated by the services agreement, the Company agreed to pay to TRC a monthly cash fee of $65,000 and issued stock options to purchase up to an aggregate of 750,000 shares of the Company’s common stock at a price per share equal to $0.89, the closing sale price of the Company’s common stock on June 24, 2009. Twenty-five percent of the stock options vested immediately and the remaining 75% were scheduled to vest pursuant to the achievement of certain milestones relating to the clinical development of cenderitide. On January 5, 2011, the final block of stock options vested. Of the 750,000 original stock options issued, 535,172 stock options vested with a total fair value of $353,976. In August 2010, the Company and TRC amended the services agreement to extend its term on a month-to-month basis and to provide for the issuance of fully-vested and immediately-exercisable stock options to purchase 250,000 shares of the Company’s common stock at an exercise price of $0.38 per share, which had an estimated fair value of $82,200 that was expensed on the date of grant. In March 2011, the Company and TRC further amended the services agreement to reduce the level of services to be provided by TRC and to reduce the monthly cash fee payable to TRC to $31,702, which monthly fee was then reduced to $30,082 in July 2011 and to $28,600 in April 2012 when certain services were eliminated. On August 1, 2012, the Company and TRC agreed that, upon the appointment of a full-time President and Chief Executive Officer during August 2012, the monthly fee payable under the services agreement would be reduced to $6,000 to reflect the termination of Mr. Kazam’s services as President and Chief Executive Officer. Additional operational and clinical development services may be provided by TRC, and billed to the Company, on an hourly basis. The Special Committee reviewed and approved the August 2010, March 2011, and August 2012 amendments to the services agreement.
	On occasion, some of the Company’s expenses are paid by TRC. No interest is charged by TRC on any outstanding balance owed by the Company. For the three and nine months ended September 30, 2013 and 2012 and for the period from August 1, 2005 (inception) through September 30, 2013, total cash services and reimbursed expenses totaled $18,000, $57,600, $46,407, $238,346, and $2,164,776, respectively. As of September 30, 2013 the Company had a payable to TRC of $18,000 which was still outstanding as of the date of this report.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2013
COMMITMENTS AND CONTINGENCIES	'
	11. COMMITMENTS AND CONTINGENCIES
	Compensation of President and CEO.
	On November 5, 2012, the Company entered into a letter agreement with Darlene Horton, M.D., its President and Chief Executive Officer, pursuant to which Dr. Horton agreed to reduce her monthly salary to $100 effective November 1, 2012, and defer the balance of her $28,314 monthly base salary (the “Deferred Salary”) until such time as the Company completes an Interim Financing Event (defined below). The term “Interim Financing Event” means the consummation on or before December 31, 2013, of one or more transactions pursuant to which the Company shall have received, whether by a financing, strategic transaction or another means (or any combination thereof), an aggregate of at least $1,000,000 in gross proceeds. As of September 30, 2013, the Company has an accrual of $253,926, representing approximately 11 months of Deferred Salary.
	On March 21, 2013, the Company entered into a letter agreement with Dr. Horton, which letter agreement amends certain compensation terms under her existing letter agreement dated August 3, 2012, as previously amended on November 5, 2012.
	Dr. Horton’s existing letter agreement provided that if, prior to the date of a “compensation adjustment event,” the Company completed a Change of Control Transaction (as defined in the agreement) and Dr. Horton’s employment was terminated by the Company (or any successor entity) without cause during the period beginning on the effective date of the Change of Control Transaction and ending on the six-month anniversary of such effective date, then she would have been entitled to receive a cash payment equal to 5% of the applicable Change of Control Proceeds (as defined in the agreement). For purposes of the agreement, the term “compensation adjustment event” means the date on which the Company secures sufficient capital, whether by a financing or strategic transaction (or any combination thereof) or another means, in order to enable the Company to initiate and fund to completion a Phase 2 clinical trial of the Company’s cenderitide product candidate.
	The March 21, 2013 letter agreement amends the payment terms described in the preceding paragraph and provides that if, prior to December 31, 2013, the Company completes a Change of Control Transaction in which either (i) the outstanding shares of the Company’s common stock are exchanged for securities of another corporation, or (ii) the Company issues shares of its common stock, with no securities or other consideration paid or payable to holders of the Company’s common stock (e.g., a merger transaction in which the Company acquires another corporation in exchange for shares of the Company’s common stock), then Dr. Horton will be entitled to receive, immediately prior to the effective time of the Change of Control Transaction, a number of shares of the Company’s common stock equal to 5% of the shares of the Company’s common stock then outstanding on a fully-diluted basis.
	The agreement further provides that if, prior to December 31, 2013, the Company completes a Change of Control Transaction other than as described in the preceding paragraph, then Dr. Horton will be entitled to receive a cash payment, on the date of such Change of Control Transaction, equal to 5% of the applicable Change of Control Proceeds (as defined in the agreement).
	Compensation of Chief Financial Officer.
	On March 21, 2013, the Company entered into a letter agreement with Daron Evans, its Chief Financial Officer, pursuant to which Mr. Evans agreed to reduce his monthly salary to $100 effective February 1, 2013, and defer the balance of his $22,917 monthly base salary until such time as the Company completes an Interim Financing Event. The term “Interim Financing Event” means the consummation on or before December 31, 2013, of one or more transactions pursuant to which the Company shall have received, whether by a financing, strategic transaction or another means (or any combination thereof), an aggregate of at least $1,000,000 in gross cash proceeds. As of September 30, 2013, the Company has an accrual of $182,533, representing approximately 8 months of deferred salary for Mr. Evans.
	In addition, the agreement provides that if, prior to December 31, 2013, the Company completes a Change of Control Transaction (as defined in the agreement) in which either (i) the outstanding shares of the Company’s common stock are exchanged for securities of another corporation, or (ii) the Company issues shares of its common stock, with no securities or other consideration paid or payable to holders of the Company’s common stock (e.g., a merger transaction in which the Company acquires another corporation in exchange for shares of the Company’s common stock), then Mr. Evans will be entitled to receive, immediately prior to the effective time of the Change of Control Transaction, a number of shares of the Company’s common stock equal to 4.5% of the shares of the Company’s common stock then outstanding on a fully-diluted basis.
	The agreement further provides that if, prior to December 31, 2013, the Company completes a Change of Control Transaction other than as described in the preceding paragraph, then Mr. Evans will be entitled to receive a cash payment, on the date of such Change of Control Transaction, equal to 4.5% of the applicable Change of Control Proceeds (as defined in the agreement).
	In consideration of the foregoing, the agreement provides that the Company shall have no further obligations pursuant to the Severance Benefits Agreement between the Company and Mr. Evans, dated July 24, 2010.
	Termination of Lease Agreement.
	On February 28, 2013, the Company terminated its office lease at 4 West 4th, Suite 400, San Mateo, CA. There were no penalties or early termination fees incurred as a result of the lease termination.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2013
SUBSEQUENT EVENTS	'
	12. SUBSEQUENT EVENTS
	On October 21, 2013, the Company and the holders of the Notes entered into an amendment to the Purchase Agreement pursuant to which the Company sold to such holders additional Notes having an aggregate principal amount of $120,510. The additional Notes have identical terms and conditions as the Notes previously issued under the Purchase Agreement (see Note 6) and were allocated among the holders on a pro rata basis based on their initial purchase of Notes. In exchange for the issuance of the Notes, the Company received aggregate gross proceeds of $102,433.

BASIS_OF_PRESENTATION_AND_SUMM1

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2013
Collaboration Income	'
	Collaboration Income
	In February 2011, the Company entered into a collaboration agreement whereby the Company was reimbursed for work performed on behalf of the collaborator upon the achievement of certain milestones. The Company recorded all of these expenses as research and development expenses and the reimbursements upon the achievement of the milestones as income (Note 5).
	The Company recognizes milestone payments as income upon achievement of the milestone only if (1) the milestone payment is non-refundable, (2) substantive effort is involved in achieving the milestone, (3) the amount of the milestone is reasonable in relation to the effort expended or the risk associated with achievement of the milestone and (4) the milestone is at risk for both parties. If any of these conditions are not met, the Company defers the milestone payment and recognizes it as income over the remaining estimated period of performance under the contract as the Company completes its performance obligations.
Research and Development	'
	Research and Development
	Research and development costs are charged to expense as incurred. Research and development includes employee costs, fees associated with operational consultants, contract clinical research organizations, contract manufacturing organizations, clinical site fees, contract laboratory research organizations, contract central testing laboratories, licensing activities, and allocated office, insurance, depreciation, and facilities expenses. The Company accrues for costs incurred as the services are being provided by monitoring the status of the trial and the invoices received from its external service providers. The Company adjusts its accruals in the period when actual costs become known. Costs related to the acquisition of technology rights for which development work is still in process are charged to operations as incurred and considered a component of research and development costs.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The Company measures fair value in accordance with generally accepted accounting principles. Fair value measurements are applied under other accounting pronouncements that require or permit fair value measurements. Financial instruments included in the Company’s balance sheets consist of cash and cash equivalents, accounts payable, accrued expenses, due to related parties, and warrant liability. The carrying amounts of these instruments reasonably approximate their fair values due to their short-term maturities.
Warrant liability	'
	Warrant Liability
	The Company accounts for the warrants issued in connection with the March 2013 convertible note issuance (Note 6) and the April 2012 financing (Note 8) in accordance with the guidance on Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, which provides that the Company classifies the warrant instrument as a liability at its fair value and adjust the instrument to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized as a component of other income or expense. The fair value of warrants issued by the Company, in connection with the April 2012 financing, have been estimated by management using a binomial options pricing model. The binomial option pricing model is a generally accepted valuation model used to generate a defined number of stock price paths in order to develop a reasonable estimate of the range of the Company’s future expected stock prices, and their resulting probabilistic valuation. In connection with the March 2013 convertible note issuance, the Company estimated the fair value of the embedded derivative warrant liability by using the Black-Scholes option-pricing model.

CONVERTIBLE_NOTES_PAYABLE_Tabl

CONVERTIBLE NOTES PAYABLE (Tables)	9 Months Ended
	Sep. 30, 2013
Schedule of Assumptions Used Valuation of Notes	'
	Management used the following assumptions for the Black-Scholes valuation of the 2013 Notes on March 15, 2013 and September 30, 2013:
		March 15, 2013			September 30, 2013
	Stock Price :	$	0.09		$	0.05
	Strike Price :	$	0.09		$	0.05
	Risk-free Rate:		0.84	%		1.39	%
	Volatility		148	%		153	%
	Term		5 years			5 years
	Probability of issuance:		50	%		95	%

FAIR_VALUE_OF_FINANCIAL_INSTRU1

FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)	9 Months Ended
	Sep. 30, 2013
Fair Value Hierarchy for Liabilities Measured at Fair Value on Recurring Basis	'
	The Company has determined the fair value of certain liabilities using the market approach. The following table presents the Company’s fair value hierarchy for these assets measured at fair value on a recurring basis as of September 30, 2013:
				Quoted Market				Significant
		Fair Value		Prices in Active		Significant Other		Unobservable
		September 30,		Markets		Observable Inputs		Inputs
		2013		(Level 1)		(Level 2)		(Level 3)
	Liabilities
	Warrant liability - April 2012 issuance	$	106,793	$	-	$	-	$	106,793
	Warrant liability - 2013 Notes		393,200		-		-		393,200
	Total	$	499,993	$	-	$	-	$	499,993
Summary of Changes in Fair Value of Liabilities and Portion of Losses Included in Income Attributable to Unrealized Appreciation that Relate to those Liabilities	'
	The following table provides a summary of changes in fair value of the Company’s liabilities, as well as the portion of losses included in income attributable to unrealized appreciation that relate to those liabilities held at September 30, 2013:
		Fair Value
		Measurements Using
		Significant
		Unobservable Inputs
		(Level 3)
		Warrant Liability
	Balance at January 1, 2013	$	63,384
	Purchases, sales and settlements:
	Derivatives issued		203,400
	Total gains or losses
	Unrealized appreciation		233,209
	Balance at September 30, 2013	$	499,993

STOCKHOLDERS_EQUITY_Tables

STOCKHOLDERS' EQUITY (Tables)	9 Months Ended
	Sep. 30, 2013
Outstanding Warrants to Purchase Shares of Common Stock	'
	Below is a table that summarizes all outstanding warrants to purchase shares of the Company’s common stock as of September 30, 2013.
						Weighted
				Exercise		Average
	Grant	Warrants		Price		Exercise		Expiration			Warrants
	Date	Issued		Range		Price		Date	Exercised		Outstanding
	7/15/09		2,909,695	$	1.25-2.28	$	1.64	7/14/14		5,000		2,904,695
	4/21/10		2,632,500	$	0.94	$	0.94	4/20/15		-		2,632,500
	4/4/12		2,512,500	$	0.5	$	0.5	4/3/17		-		2,512,500
			8,054,695			$	1.13			5,000		8,049,695

STOCK_OPTION_PLAN_Tables

STOCK OPTION PLAN (Tables)	9 Months Ended
	Sep. 30, 2013
Summary of Status of Options Issued and Information with Respect to Changes in Options Outstanding	'
	A summary of the status of the options issued under the Plan at September 30, 2013, and information with respect to the changes in options outstanding is as follows:
			Shares			Outstanding			Weighted-			Aggregate
			Available for			Stock			Average			Intrinsic
			Grant			Options			Exercise Price			Value
	Balance at January 1, 2013			4,537,522			4,571,046		$	1.24
	Options granted under the Plan			-			-		$	-
	Options exercised			-			-		$	-
	Options forfeited			2,759,341			-2,759,341		$	1.38
	Balance at September 30, 2013			7,296,863			1,811,705		$	1.02		$	-
	Exercisable at September 30, 2013						1,811,705		$	1.02		$	-
Information about Stock Options Outstanding	'
	The following table summarizes information about stock options outstanding at September 30, 2013:
				Outstanding									Exercisable
							Weighted-
							Average									Weighted-
	Range of						Remaining			Weighted-Average						Average
	Exercise Prices			Shares			Contractual Life			Exercise Price			Total Shares			Exercise Price
	$	0.09 to $0.57			696,533			3.38		$	0.45			696,533		$	0.45
	$	0.68 to $0.93			835,172			2.67		$	0.85			835,172		$	0.85
	$	1.77 to $4.50			280,000			5.17		$	2.94			280,000		$	2.94
		Total			1,811,705			3.33		$	1.02			1,811,705		$	1.02
Employee Stock-based Compensation Costs	'
	Employee stock-based compensation costs for the three and nine months ended September 30, 2013 and 2012 and for the cumulative period from August 1, 2005 (inception) through September 30, 2013 are as follows:
															Period from
															August 1, 2005
			Three months ended						Nine months ended						(inception)
			September 30,						September 30,						through September 30,
			2013			2012			2013			2012			2013
	General and administrative		$	-		$	51,210			14,845		$	237,957		$	6,822,795
	Research and development			-			-			-			67,286			1,551,203
	Total		$	-		$	51,210			14,845		$	305,243		$	8,373,998

DESCRIPTION_OF_BUSINESS_Additi

DESCRIPTION OF BUSINESS - Additional Information (Detail) (Capricor Inc [Member], USD $)	0 Months Ended
	Jul. 07, 2013
Capricor Inc [Member]	'
Diluted Percentage Of Common Stock	90.00%
Accrued Liabilities and Other Liabilities, Total	$100,000

LIQUIDITY_CAPITAL_RESOURCES_AN1

LIQUIDITY, CAPITAL RESOURCES AND MANAGEMENT'S PLANS - Additional Information (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2012	Dec. 31, 2011	Jul. 31, 2005
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]	'	'	'	'	'
Deficit accumulated during the development stage	($48,136,853)	($46,708,017)	'	'	'
Cash and cash equivalents	$71,028	$46,716	$282,507	$1,039,190	$0

BASIC_AND_DILUTED_LOSS_PER_SHA1

BASIC AND DILUTED LOSS PER SHARE - Additional Information (Detail) (Stock Options and Warrants)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Stock Options and Warrants	'	'	'	'
Earnings Per Share Disclosure [Line Items]	'	'	'	'
Securities Excluded From Calculation Of Potentially Dilutive Securities	9,861,400	16,762,331	9,861,400	16,762,331

INTANGIBLE_ASSETS_AND_INTELLEC1

INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY - Additional Information (Detail) (USD $)

3 Months Ended

9 Months Ended

98 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

98 Months Ended

1 Months Ended

12 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Feb. 15, 2011

Jul. 31, 2008

Jun. 30, 2008

Jan. 20, 2006

Dec. 31, 2008

Dec. 31, 2006

Jun. 30, 2008

Jun. 13, 2008

Jan. 20, 2006

Sep. 30, 2013

Sep. 30, 2013

Feb. 29, 2012

Feb. 29, 2012

Sep. 30, 2013

Sep. 30, 2013

Jun. 13, 2008

Jan. 20, 2006

Jan. 20, 2006

Medtronic, Inc

Medtronic, Inc

Licensing Agreement

Licensing Agreement

Licensing Agreement

Licensing Agreement

Licensing Agreement

Licensing Agreement

Licensing Agreement

Licensing Agreement

Licensing Agreement

Licensing Agreement

Collaboration Agreement

Collaboration Agreement

Cenderitide License Agreement

CU - NP License Agreement

Maximum

Maximum

Minimum

Mayo

Mayo

Mayo

Mayo

Mayo

Medtronic, Inc

Medtronic, Inc

Mayo

Mayo

Licensing Agreement

Licensing Agreement

Licensing Agreement

Grant Income

Mayo

Mayo

Mayo

Schedule of Intangible Assets Disclosure [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common shares (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

49,689

'

'

1,379,419

63,478

'

'

'

'

'

'

'

Contingent cash payments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$24,300,000

$31,900,000

'

Milestone payment

'

'

'

'

'

'

'

400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Consulting services fee annually paid

'

'

'

'

'

'

'

'

'

50,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Minimum amount of grants to be received to issue an equivalent dollar amount common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

300,000

Maximum stock value to be issued upon receipts of specified amount of grant income

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

575,000

'

Grant income

0

0

0

0

482,235

'

'

'

'

'

'

'

'

'

'

'

482,235

'

'

'

'

'

'

'

Issuance of common shares

'

'

'

'

'

'

'

'

250,000

'

250,000

500

'

'

'

'

'

'

'

'

'

'

'

'

Agreement expiration date

'

'

'

'

'

'

'

'

'

'

'

'

'

13-Jun-28

20-Jan-26

'

'

'

'

'

'

'

'

'

License agreement termination period after written notice

'

'

'

'

'

'

'

'

'

'

'

'

'

'90 days

'90 days

'

'

'

'

'

'

'

'

'

Collaboration Agreements period, after delivery

'

'

'

'

'

'

'3 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Collaboration Agreements period

'

'

'

'

'

'

'15 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of patents

'

'

'

'

'

3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reimbursement revenue

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

195,500

1,550,000

'

'

'

'

'

Fees And Expenses Payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$154,100

$39,300

'

'

'

Assumptions_for_Valuation_of_N

Assumptions for Valuation of Notes (Details) (Notes 2013, USD $)	3 Months Ended	9 Months Ended
	Mar. 15, 2013	Sep. 30, 2013
Notes 2013	'	'
Fair Value Assumptions and Methodology of Notes [Line Items]	'	'
Stock Price :	$0.09	$0.05
Strike Price :	$0.09	$0.05
Risk-free Rate:	0.84%	1.39%
Volatility	148.00%	153.00%
Term	'5 years	'5 years
Probability of issuance:	50.00%	95.00%

CONVERTIBLE_NOTES_PAYABLE_Addi

CONVERTIBLE NOTES PAYABLE - Additional Information (Detail) (USD $)	3 Months Ended	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2013	Mar. 15, 2013	Dec. 31, 2012
Debt Instrument [Line Items]	'	'	'	'
Debt Instrument, Unamortized Discount (Premium), Net	$123,204	$123,204	'	$0
Volume Weighted Average Price of Common Stock Per Share	$0.05	'	'	'
Common Stock Conversion Price Per Share	'	$0.05	'	'
Fair Value of Warrants	393,200	393,200	203,400	'
Notes 2013	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'
Debt Instrument, Maturity Date	'	15-Mar-13	'	'
Aggregate principal amount of secured convertible promissory notes	450,000	450,000	'	'
Aggregate original issue price of secured convertible promissory notes	382,500	382,500	'	'
Debt Instrument, Interest Rate, Effective Percentage	15.00%	15.00%	'	'
Debt Instrument, Payment Terms	'	'the Company shall pay to each 2013 Note holder an amount in cash equal to 175% of the principal amount then outstanding under the applicable Note.	'	'
Debt Instrument Periodic Payment Percentage	'	175.00%	'	'
Debt Instrument, Unamortized Discount (Premium), Net	30,699	30,699	'	'
Amortization of Financing Costs and Discounts	'	67,500	'	'
Notes 2013 | Fair Value, Measurements, Recurring	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'
Debt Instrument, Unamortized Discount (Premium), Net	92,505	92,505	'	'
Notes 2013 | Maximum	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'
Aggregate principal amount of secured convertible promissory notes	500,000	500,000	'	'
Aggregate original issue price of secured convertible promissory notes	$425,000	$425,000	'	'

Fair_Value_Hierarchy_for_Liabi

Fair Value Hierarchy for Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $)	Sep. 30, 2013
Fair Value, Measurements, Recurring	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Warrant liability	$499,993
Fair Value, Measurements, Recurring | April 2012 Issuance	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Warrant liability	106,793
Fair Value, Measurements, Recurring | 2013 Notes	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Warrant liability	393,200
Fair Value, Inputs, Level 1	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Warrant liability	0
Fair Value, Inputs, Level 1 | April 2012 Issuance	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Warrant liability	0
Fair Value, Inputs, Level 1 | 2013 Notes	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Warrant liability	0
Fair Value, Inputs, Level 2	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Warrant liability	0
Fair Value, Inputs, Level 2 | April 2012 Issuance	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Warrant liability	0
Fair Value, Inputs, Level 2 | 2013 Notes	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Warrant liability	0
Fair Value, Inputs, Level 3	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Warrant liability	499,993
Fair Value, Inputs, Level 3 | April 2012 Issuance	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Warrant liability	106,793
Fair Value, Inputs, Level 3 | 2013 Notes	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Warrant liability	$393,200

Summary_of_Changes_in_Fair_Val

Summary of Changes in Fair Value of Liabilities and Portion of Losses Included in Income Attributable to Unrealized Appreciation that Relate to those Liabilities (Detail) (USD $)	9 Months Ended
	Sep. 30, 2013
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'
Balance at January 1, 2013	$63,384
Purchases, sales and settlements: Derivatives issued	203,400
Unrealized appreciation	233,209
Balance at September 30, 2013	$499,993

Outstanding_Warrants_to_Purcha

Outstanding Warrants to Purchase Shares of Common Stock (Detail)	9 Months Ended
	Sep. 30, 2013
Class of Warrant or Right [Line Items]	'
Warrants Issued	8,054,695
Weighted Average Exercise Price	1.13
Exercised	5,000
Warrants Outstanding	8,049,695
Period Issuance01	'
Class of Warrant or Right [Line Items]	'
Grant Date	15-Jul-09
Warrants Issued	2,909,695
Weighted Average Exercise Price	1.64
Expiration Date	14-Jul-14
Exercised	5,000
Warrants Outstanding	2,904,695
Period Issuance01 | Minimum	'
Class of Warrant or Right [Line Items]	'
Exercise Price Range	1.25
Period Issuance01 | Maximum	'
Class of Warrant or Right [Line Items]	'
Exercise Price Range	2.28
Period Issuance02	'
Class of Warrant or Right [Line Items]	'
Grant Date	21-Apr-10
Warrants Issued	2,632,500
Exercise Price Range	0.94
Weighted Average Exercise Price	0.94
Expiration Date	20-Apr-15
Exercised	0
Warrants Outstanding	2,632,500
Period Issuance03	'
Class of Warrant or Right [Line Items]	'
Grant Date	4-Apr-12
Warrants Issued	2,512,500
Exercise Price Range	0.5
Weighted Average Exercise Price	0.5
Expiration Date	3-Apr-17
Exercised	0
Warrants Outstanding	2,512,500

STOCKHOLDERS_DEFICIT_Additiona

STOCKHOLDERS' DEFICIT - Additional Information (Detail) (USD $)

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Apr. 04, 2012

Dec. 31, 2011

Sep. 30, 2013

Aug. 01, 2013

Dec. 31, 2011

Apr. 04, 2012

Apr. 04, 2012

Apr. 04, 2012

Warrant 2012 [Member]

Warrant 2009 [Member]

Private Placement

Private Placement

Private Placement

Private Placement

Private Placement

Private Placement

Private Placement

Private Placement

Warrant

Officers And Executive Officers

Roth Capital Partners, LLC

Common Stock

Statement [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common shares

'

'

'

'

3,350,000

'

'

'

'

275,000

'

'

Common stock purchase price per share

'

'

'

'

$0.40

'

'

'

'

'

'

'

Exercise price of warrant

'

'

'

'

'

'

'

'

'

'

'

0.5

Warrant issued

'

'

'

'

2,512,500

'

'

'

'

'

'

'

Warrant term

'

'

'

'

'5 years

'5 years

'

'

'

'

'

'

Proceeds from Securities issued to investors

'

'

'

'

$1,340,000

'

'

'

'

'

'

'

Placement agent cost of stock issued

'

'

'

'

140,000

'

'

'

'

'

'

'

Cash Fee Amount Paid

'

'

'

'

'

'

'

'

'

'

110,000

'

Cash fee paid to placement Agents

'

'

'

'

'

'

'

'

'

'

35,000

'

Issuance of warrant to purchase shares of common stock

'

'

2,503,125

1,484,695

'

'

'

'

'

206,250

'

'

Payments For Purchase Of Common Stock

'

'

110,550

'

'

'

'

'

'

110,000

'

'

Warrant liability

499,993

63,384

'

'

600,000

'

100,000

'

'

'

'

'

Weighted average term of warrants

'3 years 6 months

'

'

'

'

'

'

'

'

'

'

'

Warrants expected volatility rate

153.00%

'

'

'

'

'

'

'

'

'

'

'

Warrants expected risk free interest rate

1.39%

'

'

'

'

'

'

'

'

'

'

'

Warrants issued, shares

8,054,695

'

'

'

'

'

'

2,750,000

2,500,000

'

'

'

Warrants issued for agents, exercise price per share

'

'

'

'

'

$0.60

'

'

'

'

'

'

Warrants issued for agents, shares

'

'

'

'

'

250,000

'

'

'

'

'

'

Class Of Warrant Or Right Exercises In Period Weighted Average Exercise Price Of Warrants Or Rights

1.13

'

'

'

'

'

'

0.1667

'

'

'

'

Class of Warrant or Right, Outstanding

8,049,695

'

'

'

'

'

'

458,332

'

'

'

'

Warrants and Rights Outstanding

'

'

'

'

'

'

'

$13,750

'

'

'

'

Shares, Issued

'

'

'

0.01102

'

'

'

'

'

'

'

'

Common Stock Shares Issued

43,520,563

43,062,231

'

16,360

'

'

'

'

'

'

'

'

Summary_of_Status_of_Options_I

Summary of Status of Options Issued and Information with Respect to Changes in Options Outstanding (Detail) (USD $)	9 Months Ended
	Sep. 30, 2013
Shares Available for Grant	'
Balance at January 1, 2013	4,537,522
Options granted under the Plan	0
Options exercised	0
Options forfeited	2,759,341
Balance at September 30, 2013	7,296,863
Outstanding Stock Options	'
Balance at January 1, 2013	4,571,046
Options granted under the Plan	0
Options exercised	0
Options forfeited	-2,759,341
Balance at September 30, 2013	1,811,705
Exercisable at September 30, 2013	1,811,705
Weighted-Average Exercise Price	'
Balance at January 1, 2013	$1.24
Options granted under the Plan	$0
Options exercised	$0
Options forfeited	$1.38
Balance at September 30, 2013	$1.02
Exercisable at September 30, 2013	$1.02
Aggregate Intrinsic Value	'
Balance at September 30, 2013	$0
Exercisable at September 30, 2013	$0

Information_about_Stock_Option

Information about Stock Options Outstanding (Detail) (USD $)	9 Months Ended
	Sep. 30, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Outstanding, Shares	1,811,705
Outstanding, Weighted-Average Remaining Contractual Life	'3 years 3 months 29 days
Outstanding, Weighted-Average Exercise Price	$1.02
Exercisable, Total Shares	1,811,705
Exercisable, Weighted-Average Exercise Price	$1.02
Range One	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Range of Exercise Prices, lower range	$0.09
Range of Exercise Prices, upper range	$0.57
Outstanding, Shares	696,533
Outstanding, Weighted-Average Remaining Contractual Life	'3 years 4 months 17 days
Outstanding, Weighted-Average Exercise Price	$0.45
Exercisable, Total Shares	696,533
Exercisable, Weighted-Average Exercise Price	$0.45
Range Two	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Range of Exercise Prices, lower range	$0.68
Range of Exercise Prices, upper range	$0.93
Outstanding, Shares	835,172
Outstanding, Weighted-Average Remaining Contractual Life	'2 years 8 months 1 day
Outstanding, Weighted-Average Exercise Price	$0.85
Exercisable, Total Shares	835,172
Exercisable, Weighted-Average Exercise Price	$0.85
Range Three	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Range of Exercise Prices, lower range	$1.77
Range of Exercise Prices, upper range	$4.50
Outstanding, Shares	280,000
Outstanding, Weighted-Average Remaining Contractual Life	'5 years 2 months 1 day
Outstanding, Weighted-Average Exercise Price	$2.94
Exercisable, Total Shares	280,000
Exercisable, Weighted-Average Exercise Price	$2.94

Employee_Stockbased_Compensati

Employee Stock-based Compensation Costs (Detail) (USD $)	3 Months Ended		9 Months Ended		98 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'	'
Stock-based compensation cost	$0	$51,210	$14,845	$305,243	$8,373,998
General and Administrative Expense	'	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'	'
Stock-based compensation cost	0	51,210	14,845	237,957	6,822,795
Research and Development Expense	'	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'	'
Stock-based compensation cost	$0	$0	$0	$67,286	$1,551,203

STOCK_OPTION_PLAN_Additional_I

STOCK OPTION PLAN - Additional Information (Detail) (USD $)

Sep. 30, 2013

Dec. 31, 2012

Aug. 09, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Jul. 26, 2010

Sep. 17, 2007

Aug. 10, 2005

Sep. 30, 2013

Sep. 30, 2013

Nile or Nile stock option holders

Stock Option Plan, Twenty Zero Five

Stock Option Plan, Twenty Zero Five

Stock Option Plan, Twenty Zero Five

Stock Option Plan, Twenty Zero Five

Stock Option Plan, Twenty Zero Five

Stock Option Plan, Twenty Zero Five

Stock Option Plan, Twenty Zero Five

Stock Option Plan, Twenty Zero Five

Stock Option Plan, Twenty Zero Five

Stock Option Plan, Twenty Zero Five

Maximum

Minimum

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation, common stock authorized

'

'

'

'

'

'

'

'

9,500,000

'

2,000,000

'

'

Share-based compensation amendment pursuant to the merger, number of shares substituted for each share of stock then subject to plan

'

'

'

'

'

'

'

'

'

2.758838

'

'

'

Share-based compensation, shares available under stock option plan

7,296,863

4,537,522

'

'

'

'

'

'

'

5,517,676

'

'

'

Share-based compensation, stock option term

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

Share-based compensation, stock option plan vesting period

'

'

'

'

'

'

'

'

'

'

'

'4 years

'1 year

Share-based compensation, fair value of the shares vested

'

'

'

$0

$14,862

$217,101

$625,961

$7,620,918

'

'

'

'

'

Share Based Compensation Non Employees

'

'

'

$0

$0

$0

$0

$498,095

'

'

'

'

'

Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit

'

'

$0.30

'

'

'

'

'

'

'

'

'

'

Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit

'

'

$4.50

'

'

'

'

'

'

'

'

'

'

Common Stock Termination Of Stock Option Rights

'

'

1,774,341

'

'

'

'

'

'

'

'

'

'

RELATED_PARTIES_Additional_Inf

RELATED PARTIES - Additional Information (Detail) (USD $)

Sep. 30, 2013

Dec. 31, 2012

Aug. 31, 2012

Apr. 30, 2012

Jul. 31, 2011

Mar. 31, 2011

Jan. 05, 2011

Aug. 31, 2010

Jun. 24, 2009

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Two River Consulting

Two River Consulting

Two River Consulting

Two River Consulting

Two River Consulting

Two River Consulting

Two River Consulting

Two River Consulting

Two River Consulting

Two River Consulting

Two River Consulting

Two River Consulting

Related Party Transaction [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Services agreement period

'

'

'

'

'

'

'

'

'1 year

'

'

'

'

'

Monthly cash compensation fee for services

'

'

$6,000

$28,600

$30,082

$31,702

'

'

$65,000

'

'

'

'

'

Share-based compensation for non-employees services, issuance of stock options

'

'

'

'

'

'

'

250,000

750,000

'

'

'

'

'

Share-based compensation for non-employees services, issuance of stock options, price per share

'

'

'

'

'

'

'

'

$0.89

'

'

'

'

'

Share-based compensation for non-employees services, percentage of stock options vested

'

'

'

'

'

'

'

'

25.00%

'

'

'

'

'

Share-based compensation for non-employees services, percentage of stock options scheduled to vest pursuant to achievement of certain milestones

'

'

'

'

'

'

'

'

75.00%

'

'

'

'

'

Share-based compensation for non-employees services, options vested, shares

'

'

'

'

'

'

535,172

'

'

'

'

'

'

'

Share-based compensation for non-employees services, fair value of options vested

'

'

'

'

'

'

353,976

82,200

'

'

'

'

'

'

Share-based compensation for non-employees services, stock option exercise price per share

'

'

'

'

'

'

'

$0.38

'

'

'

'

'

'

Total cash services and reimbursed expenses

'

'

'

'

'

'

'

'

'

18,000

57,600

46,407

238,346

2,164,776

Amount payable to related party

$18,000

$16,139

'

'

'

'

'

'

'

$18,000

'

$18,000

'

$18,000

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES - Additional Information (Detail) (USD $)	1 Months Ended	9 Months Ended
	Nov. 05, 2012	Sep. 30, 2013
Commitments and Contingencies Disclosure [Line Items]	'	'
Termination of Lease Agreement	'	'On February 28, 2013, the Company terminated its office lease at 4 West 4th, Suite 400, San Mateo, CA. There were no penalties or early termination fees incurred as a result of the lease termination.
President and Chief Executive Officer	'	'
Commitments and Contingencies Disclosure [Line Items]	'	'
Reduced Monthly Salary	$100	'
Monthly base salary	28,314	'
Threshold Amount For Any Future Financing	'	1,000,000
Percentage Of Cash Payment Received	'	5.00%
Percentage Of Common Stock Shares Received	'	5.00%
Accrued Salaries, Current	'	253,926
Chief Financial Officer	'	'
Commitments and Contingencies Disclosure [Line Items]	'	'
Reduced Monthly Salary	'	100
Monthly base salary	'	22,917
Threshold Amount For Any Future Financing	'	1,000,000
Percentage Of Cash Payment Received	'	4.50%
Percentage Of Common Stock Shares Received	'	4.50%
Accrued Salaries, Current	'	$182,533

SUBSEQUENT_EVENTS_Additional_I

SUBSEQUENT EVENTS - Additional Information (Detail) (Subsequent Event, USD $)	9 Months Ended
	Sep. 30, 2013
Subsequent Event	'
Debt Instrument, Face Amount	$120,510
Proceeds from Issuance of Debt	$102,433